MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Kura Oncology Inc

Abrir

SetorSaúde

6.41 0.79

Visão Geral

Variação de preço das ações

24h

Atual

Mín

6.11

Máximo

6.43

Indicadores-chave

By Trading Economics

Rendimento

35M

-19M

Vendas

54M

54M

EPS

-0.22

Margem de lucro

-35.664

Funcionários

192

EBITDA

43M

-17M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+284.14% upside

Dividendos

By Dow Jones

Próximos Ganhos

1 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-114M

499M

Abertura anterior

5.62

Fecho anterior

6.41

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2025, 23:54 UTC

Ações em Alta

Stocks to Watch: Alphabet, Intel, AppFolio

24 de abr. de 2025, 23:51 UTC

Conversa de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 de abr. de 2025, 23:37 UTC

Principais Notícias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 de abr. de 2025, 23:36 UTC

Principais Notícias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 de abr. de 2025, 23:13 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 de abr. de 2025, 23:09 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 de abr. de 2025, 22:51 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 de abr. de 2025, 22:48 UTC

Principais Notícias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 de abr. de 2025, 22:47 UTC

Conversa de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 de abr. de 2025, 22:38 UTC

Conversa de Mercado
Ganhos

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 de abr. de 2025, 22:24 UTC

Conversa de Mercado
Ganhos

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 de abr. de 2025, 22:23 UTC

Ganhos

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 de abr. de 2025, 22:09 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 de abr. de 2025, 22:00 UTC

Conversa de Mercado
Ganhos

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 de abr. de 2025, 21:39 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 de abr. de 2025, 21:23 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 de abr. de 2025, 21:04 UTC

Ganhos

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 de abr. de 2025, 21:02 UTC

Ganhos

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

284.14% parte superior

Previsão para 12 meses

Média 24.7 USD  284.14%

Máximo 40 USD

Mínimo 10 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

10

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

5.77 / 6.6Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.